Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (November 2021)
25 slides from Sutro Biopharma's investor presentation, Nov 10, 2021
Slide 1: Company Overview November 2021
NON-CONFIDENTIAL Company Overview November 2021 Sutro Biopharma NASDAQ: STRO Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements NON-CONFIDENTIAL 2 This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statemen
Slide 3: Pioneer and Leader in Cell-Free Technology
Pioneer and Leader in Cell-Free Technology Optimizing cell-free platform for ADCs and beyond Establish cell-free ecosystem Building ecosystem through strategic partnerships Multiple ADC programs showcasing platform breadth Additional value creation through spinout New modalities and extended value c
Slide 4: Industry Leading Cell-Free Protein Synthesis Platform
Industry Leading Cell-Free Protein Synthesis Platform GMP production yields consistent and scalable end-products 1 2 3 4 5 6 Stockpiled Extract Grow Cells from E. Coli Cell Lysis Cellular Extract Cell-Free Protein Synthesis 7 IgG with Non- Natural Amino Acids Linker-Warhead Click Chemistry Homogenou
Slide 5: Advantages of Precision Protein Therapeutics
Advantages of Precision Protein Therapeutics Homogenous, precisely designed complex biologics with optimized performance Months to discover lead drug candidates using transient stable cell lines evaluating a handful of candidates Heterogeneous mixtures have less favorable therapeutic window due to v
Slide 6: Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer
Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer (1) Novel and precise design to drive adaptive and protective immune responses Cytokine Derivative Enhanced tumor targeting of cytotoxic payloads Prodrug cytokine targeting functional cytokine to tumor Bispecific ADC Prodrug Cytoki
Slide 7: Cell-Free Platform Delivering Robust Pipeline
Cell-Free Platform Delivering Robust Pipeline Four product candidates in the clinic and late-stage discovery programs STRO-001 is partnered with BioNova Pharmaceuticals Limited for development in Greater China, including mainland China, Hong Kong, Macau, and Taiwan EMD Serono is the biopharmaceutica
Slide 8: FolRα-Targeting ADC: STRO-002
NON-CONFIDENTIAL FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002
Slide 9: STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers
STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers STRO 002 STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate- receptor alpha (FolRα): 1 FolRα is overexpressed in certain cancers including ovarian cancer and endometrial cancer 2 P
Slide 10: STRO-002 Dose-Escalation Cohort Completed
Study Update: Dose-escalation enrollment completed August 2020 Updated dose-escalation data as of April 23, 2021 was presented at 2021 ASCO Annual Meeting in June 2021 STRO 002 Part 1: Dose-Escalation Cohort in Ovarian STRO-002-GM1 Dose-Escalation Cohort Has Been Completed Heavily pre-treated ovaria
Slide 11: STRO-002 Was Generally Well Tolerated
STRO-002 Was Generally Well Tolerated 86% of TEAEs remain Grade 1-2 and no observed ocular toxicity signal Dose Levels in Dose-Escalation Common TEAEs > 25% By Grade (2) MTD was not reached; DLTs occurred in 2 patients: Grade 2 neuropathy/Grade 3 arthralgia at 6.0 mg/kg and Grade 3 bone pain at 6.4
Slide 12: Tumor Reduction Observed in Majority of Patients
STRO 002 (1) Maximum % change from baseline in sum of longest diameter in evaluable patients treated with STRO-002 at ≥ 2.9 mg/kg Objective Response was observed in 10 patients Treatment ongoing as of April 23, 2021 -30% Partial Response Maximum Change (1) in Tumor Target Lesions (N=31) 20% 0% Start
Slide 13: Tumor Regression and Control Over Time
20 -30 -100 0 0 13 26 65 78 Weeks since first treatment 39 52 Change from baseline (%) Best Overall Response (BOR) PD SD PRu PR CR Treatment ongoing as of April 23, 2021 CR (1) Tumor Regression and Control Over Time Deepening of responses and two patients with prolonged stable disease remaining on s
Slide 14: Clinical Benefit Seen in Heavily Pre-Treated Patient Population
Weeks since first treatment Individual patients treated with STRO-002 Treatment Duration (1) and Response, Based on Evaluable Patients (N=31) Clinical Benefit Seen in Heavily Pre-Treated Patient Population Median duration of response is 5.8 months and three patients remained on study at over 18 mont
Slide 15: Favorable PFS Compared to Chemotherapy and Other Agents
STRO 002 Favorable PFS Compared to Chemotherapy and Other Agents Based on Kaplan-Meier estimates, median PFS was 7.2 months PFS is calculated on 39 patients from the time from the first dose of study treatment until the time of death or progressive disease (PD) whichever occurs first. If no death or
Slide 16: FolRα-Expression by Immunohistochemistry
STRO 002 FolRα-Expression by Immunohistochemistry Responses and anti-tumor activity observed across various FolRα-expression levels Best Overall Response (BOR) PR PRu SD PD (1) Assessed by Ventana FOLR1 expression assay based on available archival tissue from dose-escalation patients and scored usin
Slide 17: Expanding the STRO-002 Franchise
STRO 002 Expanding the STRO-002 Franchise Enrollment completed in Dose-Expansion Cohort and new studies initiated 39 patients, 31 evaluable at active doses Enrollment completed Aug 2020 Unselected for FolRα-expression levels Median of 6 prior lines of therapy Updated at ASCO 2021 1 CR, 4 PRs and 5 u
Slide 18: CD74-Targeting ADC: STRO-001
NON-CONFIDENTIAL CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001
Slide 19: Stable CD74 Targeting ADC for Hematological Cancers
Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects 1 Potential First-in-Class Molecule for Patients with NHL and MM STRO 001 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: Comprises two non-cleava
Slide 20: STRO-001-BCM1 Study Design and Updates
R/R multiple myeloma (N=30) R/R NHL (N=30) Cohort A Cohort B RP2D RP2D STRO-001-BCM1 Dose-Escalation Study STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose-escalation study with NHL update at ASH 2020 STRO 001 NHL Cohort Update at ASH 2020 0.91 mg/kg† 1.27 mg/kg† 1.78 mg/kg† 2.5 mg/kg† 3.
Slide 21: ASH 2020 Update in NHL Cohort
ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies STRO 001 Note: Data as of October 30, 2020 from ASH 2020 NON-CONFIDENTIAL 21
Slide 22: Encouraging Interim Treatment Duration and Responses
Responses to STRO-001 Treatment Duration Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL patients who had progressed on CAR-T STRO 001 (1) 18 patients are evaluable for response as of October 30, 2020 Note: Data as of October 30, 2020 from ASH 2020 0 50 100 * Pati
Slide 23: Financial Overview
Financial Overview Well-capitalized through cash and other financial sources NON-CONFIDENTIAL 23 $254.2M in cash, cash equivalents & marketable securities as of Sept. 30, 2021 Projected cash runway into 2H 2023, based on current business plans and assumptions ~1.6M shares of Vaxcyte (Nasdaq: PCVX) n
Slide 24: Driving Value Through Advancing Programs
Driving Value Through Advancing Programs Prioritizing expanding the STRO-002 franchise NON-CONFIDENTIAL 24
Slide 25: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD President of Research and Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini, MBA Chief Financial Officer Shabbir Anik, PhD Chief Technical
Sutro Biopharma — Investor Presentation (November 2021) on 6ix